Introduction to the DELIVER-MS Trial

Determining the optimal therapeutic path for Multiple Sclerosis (MS) is a complex challenge for clinicians and patients alike. Recent results from the DELIVER-MS trial provide crucial insights into MS treatment decision-making among treatment-naïve patients. This study compared two primary strategies: early high-efficacy therapy (EHT) and the traditional escalation (ESC) approach. Understanding these preferences is vital for personalizing care in the evolving landscape of neurology.

Study Design and Participation Trends

The DELIVER-MS trial utilized a multi-center pragmatic design. It included both a randomized controlled trial (RCT) and a parallel observational study (OBS). Researchers enrolled 816 participants across 31 sites in the UK and US. Interestingly, a large number of patients declined randomization. The primary reason for this refusal was a strong preference for a specific disease-modifying therapy (DMT). Additionally, safety and efficacy concerns significantly influenced these patient choices.

Factors Influencing MS Treatment Decision-Making

Within the observational cohort, a significant majority (67%) of participants chose the early high-efficacy therapy route. In contrast, only 33% opted for the escalation strategy. Several key factors predicted the choice of EHT. For instance, patients with higher educational attainment were more likely to select high-efficacy treatments from the outset. Furthermore, the local availability of EHT drugs at specific clinical sites played a major role in the selection process. Consequently, institutional resources and clinician influence remain pivotal in the therapeutic journey.

The data also highlighted distinct differences between the RCT and OBS groups. Patients in the RCT cohort generally had lower relapse rates. Moreover, they exhibited a greater brain parenchymal fraction compared to those in the observational group. These findings suggest that baseline disease severity and individual patient priorities significantly shape the MS treatment decision-making process.

Clinical Implications for Practice

Neurologists must balance evidence-based outcomes with unique patient preferences. The shift toward EHT reflects a growing clinical confidence in aggressive early intervention to preserve brain volume. However, the study also underscores that barriers like education and drug availability persist. Therefore, shared decision-making models should address these socioeconomic and systemic factors to optimize long-term patient outcomes.

Frequently Asked Questions

What were the main reasons patients declined randomization in the DELIVER-MS trial?

The majority of participants (85%) declined randomization because they had a strong preference for a particular DMT. Other reasons included concerns about treatment efficacy (20%) and drug safety (9%).

Which patient factors were associated with choosing EHT over escalation?

The choice of early high-efficacy therapy was strongly associated with higher patient education levels and the specific clinical site's availability of EHT options. This highlights the impact of both patient demographics and healthcare infrastructure on treatment selection.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Tallantyre EC et al. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Mult Scler. 2026 May 31. doi: 10.1177/13524585261449988. PMID: 42218617.

Giovannoni G, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:5-48.

Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. JAMA. 2020;324(18):1877-1891.